<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058717</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY12579</org_study_id>
    <nct_id>NCT04058717</nct_id>
  </id_info>
  <brief_title>Low Nicotine Cigarettes Plus Electronic Cigarettes</brief_title>
  <official_title>Randomized Trial of Low Nicotine Cigarettes Plus Electronic Cigarettes in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the health effects of very low nicotine content in cigarettes,
      in conjunction with the availability of nicotine-containing electronic cigarettes (e-cigs)
      among smokers with mental health conditions (SMHC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific objective of this study is to recruit a cohort of 240 current exclusive daily
      SMHC (diagnosed using the MINI International Neuropsychiatric Interview) and to measure a
      comprehensive battery of behavioral and health indicators at 4, 8, 12 and 16 weeks after
      being randomized to use either normal nicotine content (NNC) Spectrum cigarettes (11.6 mg
      nicotine/cigarette) or very low nicotine content (VLNC) Spectrum cigarettes (0.2 mg
      nicotine/cigarette) while also having access to an electronic cigarette (containing either 0
      nicotine or high nicotine e-liquid) in a randomized double-blind, placebo-controlled, 2 by 2
      design. All participants will be followed up with a study visit 4 weeks after the final
      randomized visit to identify whether they have continued to use e-cigs/cigarettes and to
      assess their motivation in smoking abstinence.

      Our central hypothesis is that key markers of harms to health (e.g. urinary NNAL, exhaled CO,
      measures of addiction, and mental distress) will be significantly improved among SMHC who are
      provided VLNC cigarettes and high nicotine e-cigs.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 X 2 factorial design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol)</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of tobacco-specific nitrosamine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Carbon Monoxide</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of cigarette smoke exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kessler-6 score</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of serious psychological distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn State Cigarette Dependence Index</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of cigarette dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn State Electronic Cigarette Dependence Index</measure>
    <time_frame>Week 16</time_frame>
    <description>Measure of e-cigarette dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarette abstinence</measure>
    <time_frame>Week 20</time_frame>
    <description>No cigarette use in the past 7 days and exhaled carbon monoxide &lt; 6ppm</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>NNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Nicotine Content research cigarettes</intervention_name>
    <description>Research cigarettes with 11.6 mg nicotine/cigarette.</description>
    <arm_group_label>NNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>NNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Nicotine e-cigarette</intervention_name>
    <description>E-cigarette containing high nicotine e-liquid</description>
    <arm_group_label>NNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>VLNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very Low Nicotine Content research cigarettes</intervention_name>
    <description>Research cigarettes with 0.2 mg nicotine/cigarette.</description>
    <arm_group_label>VLNC cigarettes + High Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>VLNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zero Nicotine e-cigarette</intervention_name>
    <description>E-cigarette containing zero nicotine e-liquid</description>
    <arm_group_label>NNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
    <arm_group_label>VLNC cigarettes + Zero Nicotine Containing E-cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoke &gt;5 cigarettes per day for at least the prior 12 months

          -  Smoke regular, filtered cigarettes or machine-rolled cigarettes with a filter

          -  Exhaled CO measurement of ≥ 6 parts per million at baseline

          -  No serious cigarette smoking quit attempt or use of any FDA-approved smoking cessation
             medication in the prior 30 days (includes any nicotine replacement, varenicline,
             bupropion [used specifically as a quitting aid])

          -  No plans to quit smoking within the next 3 weeks

          -  Must be willing to both switch to a different type of cigarette that may contain a
             different amount of nicotine and to try an e-cig to substitute for some of their
             cigarettes

          -  Must be willing and able to respond to contacts from study staff or attend visits over
             the study period (not planning to move, not planning extended vacation, no planned
             surgeries)

          -  Must meet lifetime diagnostic criteria for a current or lifetime unipolar or bipolar
             mood disorder (dysthymia, major or minor depression, premenstrual dysphoric disorder,
             manic episode, hypomanic episode, bipolar disorder), an anxiety disorder (panic
             disorder, obsessive-compulsive disorder; post-traumatic stress disorder; mixed anxiety
             depressive disorder, agoraphobia, generalized anxiety disorder, social phobia,
             specific phobia), a psychotic disorder (schizophrenia, schizoaffective disorder,
             schizophreniform disorder, or other psychotic disorder), an eating disorder (anorexia
             or bulimia), or attention-deficit/hyperactivity disorder based on the
             MINI-International Neuropsychiatric Interview.

          -  Able to read and write in English

          -  Able to understand and give informed consent

        Exclusion Criteria:

          -  Women who are pregnant and/or nursing or trying to become pregnant

          -  Unstable or significant medical condition in the past 3 months (e.g., recent heart
             attack or other serious heart condition, stroke, severe angina, high blood pressure
             [systolic &gt;159 mmHg or diastolic &gt;99 mmHg during screening)

          -  Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require
             oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe
             immune system disorders (e.g., uncontrolled HIV/AIDS, multiple sclerosis symptoms) or
             any medical disorder/medication that may affect participant safety or biomarker data

          -  Uncontrolled mental illness or substance abuse, or inpatient treatment for these in
             the past 6 months

          -  Current suicide risk on clinical assessment (above &quot;low risk&quot; score (or ≥ 9) on MINI
             diagnostic interview suicide module during screening (34))

          -  Use of any non-cigarette nicotine delivery product (e.g., pipe, cigar, dip, chew,
             snus, hookah, e-cig, strips or sticks, IQOS) in the past 7 days at screening

          -  Use of an e-cig for 5 or more days in the past 28 days or any use in the past 7 days
             at screening

          -  Use of marijuana or other illegal drugs/prescription drugs for non-medical use
             daily/almost daily or weekly in the past 3 months per NIDA Quick Screen

          -  Any known allergy to propylene glycol or vegetable glycerin

          -  Surgery requiring general anesthesia in the past 6 weeks

          -  History of difficulty providing or unwilling to provide blood samples (fainting,
             seizures, poor veins, anxiety)

          -  Unwilling to remain on one flavor of cigarette (regular or menthol) for the duration
             of the trial

          -  Previous use of SPECTRUM research cigarettes in the past 6 months

          -  Other member of household currently participating in the study

          -  History of a seizure disorder or had a seizure in the past 12 months

          -  Currently taking or have taken medications prescribed to prevent seizures (such as
             Carbamazepine or Phenobarbital). Using seizure medications for off-label use
             (indications other than treatment for seizures) will not be included as an exclusion,
             these will be assessed on a case-by-case basis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Foulds, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolle Krebs, MS</last_name>
    <phone>717-531-5673</phone>
    <email>nkrebs@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan Foulds, PhD</last_name>
    <phone>717-531-3504</phone>
    <email>jfoulds@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Foulds</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

